Pulmonary arterial hypertension targeted for new treatment by University of 葫芦影业 scientists
Scientists at the University of 葫芦影业, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).